Quest Diagnostics (DGX) Tops Q4 EPS by 4c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Quest Diagnostics (DGX) PT Raised to $96 at Jefferies Following 4Q Earnings Report
January 27, 2017 9:03 AM ESTJefferies raised its price target on Quest Diagnostics (NYSE: DGX) to $96.00 (from $86.00) while maintaining a Hold rating. DGX posted its 5th consecutive quarter of positive organic volume growth, which yielded a $0.04/3% EPS beat on in-line EBITDA.
Analyst Brian Tanquilut commented, "We... More
